このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Study in Human iPSCs-derived RPE Cells Transplantation for Advanced (Late-stage) AMD

Study in Human iPSCs-derived Retinal Pigment Epithelium Cells Transplantation for Advanced (Late-stage) Age-Related Macular Degeneration

Phase I Study of the Safety and Preliminary Efficacy of Human induced pluripotent stem cells-derived Retinal Pigment Epithelial Cells (hiPSC-RPEs) Subretinal Transplantation in Adanced (Late-Stage) Age-Related Macular Degeneration(AMD) Patients.

調査の概要

状態

募集

研究の種類

介入

入学 (推定)

12

段階

  • フェーズ2
  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Jiangsu
      • Nanjing、Jiangsu、中国、210029
        • 募集
        • The First Affiliated Hospital with Nanjing Medical University
        • コンタクト:
          • Yue Wang
          • 電話番号:+86 13405818362

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

50年~85年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • (1)Age ≥50 years and ≤85 years, regardless of gender.
  • (2)Patients with atrophic AMD in the macular area (geographic atrophy >250μm, involving the foveal center); or inactive neovascular AMD patients who have undergone treatment for wet AMD or have naturally converted to non-exudative AMD (referring to patients with fibrovascular scar formation, who are unresponsive to anti-VEGF treatment, and have no macular edema on OCT and/or no fluorescein leakage on FFA), with a scar diameter not exceeding 6 PD.
  • (3)Best-corrected visual acuity (BCVA) of the study eye ≥5 letters and ≤34 letters (using the ETDRS visual acuity chart).
  • (4)If both eyes meet the criteria, the more severely affected eye will be selected; if the severity is the same in both eyes, the right eye will be designated as the study eye.
  • (5)The patient or their legal representative has signed a written informed consent form.

Exclusion Criteria:

  • Ocular Diseases:
  • (1)Vitreous hemorrhage in the study eye within 2 months prior to screening.
  • (2)Presence of a scar or fibrosis involving the fovea in the study eye, or a peripheral scar area greater than 6 PD, indicating severe irreversible visual loss.
  • (3)Presence of pseudoexfoliation syndrome, central retinal vein occlusion, intraocular hemorrhage causing visual loss, rhegmatogenous retinal detachment, macular hole, or active choroidal neovascularization in the study eye.
  • (4)Afferent pupillary defect (APD) in the study eye.
  • (5)Significant media opacity in the study eye (excluding lens opacities) that may interfere with visual function assessment or fundus examination.
  • (6)Acute infectious inflammation in either eye during the screening period.
  • (7)Patients with intraocular pressure higher than 25 mmHg despite medical treatment.
  • (8)Monocular blind patients.

Ocular Treatments:

  • (9)The study eye has undergone focal/grid laser photocoagulation within 3 months prior to screening.
  • (10)The study eye has undergone any intraocular surgery within 3 months prior to screening.
  • (11) Any eye has received anti-angiogenic therapy (including any anti-VEGF agents, e.g., Aflibercept [Eylea®], Ranibizumab [Lucentis®], Bevacizumab [Avastin®]) within 1 month prior to screening; or has undergone cataract surgery within 1 month prior to screening with unstable postoperative ocular conditions.

Systemic Diseases, Treatments, and Other Conditions:

  • (12)Patients with an allergic reaction or history of allergy to sodium fluorescein and indocyanine green, a history of allergy to protein products used for treatment or diagnosis, and patients with allergies to two or more drugs and/or non-drug factors, or those currently suffering from allergic diseases.
  • (13)Patients with uncontrolled diabetes (fasting blood glucose ≥7.0 mmol/L or 2-hour postprandial blood glucose ≥11.1 mmol/L).
  • (14)Patients with a history of surgical procedures within 1 month prior to screening, or those with unhealed wounds, ulcers, fractures, etc.
  • (15)Patients with uncontrolled hypertension (defined as a single measurement of systolic blood pressure >180 mmHg, two consecutive measurements of systolic blood pressure >160 mmHg, or diastolic blood pressure >100 mmHg despite optimal treatment).
  • (16)Patients with a history of myocardial infarction within 6 months prior to enrollment.
  • (17)Patients with active disseminated intravascular coagulation or a significant tendency to bleed; patients who have used anticoagulant or antiplatelet aggregation drugs within 14 days prior to screening, except for aspirin/nonsteroidal anti-inflammatory drugs.
  • (18) Presence of any uncontrolled systemic clinical conditions, such as interstitial pneumonia, severe psychiatric, neurological, cardiovascular, or respiratory diseases, malignant tumors, Parkinson's disease, Alzheimer's disease, or other severe systemic disorders.
  • (19)Women of childbearing age with a positive pregnancy test during the screening period. Women who wish to breastfeed during the study period, and all patients of childbearing age (male and female) who do not agree to take effective contraceptive measures (such as intrauterine devices, oral contraceptives, or condoms) throughout the study period and for 30 days after the end of the visit period.
  • (20)Patients who have participated in or are currently participating in other clinical studies within 30 days prior to screening.
  • (21)Hemoglobin <100 g/L, platelets ≤100×10^9/L, neutrophil count <1.0×10^9/L, ALT/AST >1.5×upper limit of normal (ULN), creatinine >1.3 mg/dL.
  • (22)Subjects with any clinically significant finding in virological tests (HIV, HBV, HCV and TPPA).
  • (23)Patients deemed unsuitable for inclusion by the investigator, or other medical conditions that limit the subject's compliance, safety, or affect the results of the trial results.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:順次割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:HiO-630 Dose-Escalation Cohorts

Participants will receive a single subretinal injection of HiO-630. Three ascending dose cohorts are included: 200,000 cells/eye (low dose), 400,000 cells/eye (mid dose), and 600,000 cells/eye (high dose). Enrollment into the next higher-dose cohort will commence upon completion of safety assessment for the preceding cohort.

hiPSC-RPEs transplantation directly into the subretinal space of one eye (experimental eye) in a single transplant procedure

他の名前:
  • HiO-630

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Incidence and Severity of Treatment-Related Adverse Events
時間枠:Within 2 years after administration

Any adverse reactions/adverse events (AEs) related to hiPSC-RPEs treatment occurring within 2 years after the completion of hiPSC-RPEs administration in all subjects, and their severity (graded according to CTCAE criteria).

Within 2 years after administration

二次結果の測定

結果測定
メジャーの説明
時間枠
Assessment of visual acuity using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart.
時間枠:From enrollment to the end of study at 12 months

Best-corrected visual acuity (BCVA) of the study eye and fellow eye will be measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart. Subjects wearing soft contact lenses shall remove the lenses and wait for 30 minutes prior to the examination.

Under standard illumination conditions, subjects wear their best refractive correction, occlude the non-tested eye, and identify letters line-by-line at a distance of 4 meters. One point is awarded for each correctly identified letter. If ≥20 letters are correctly identified at 4 meters, the ETDRS score equals the number of letters correctly read at 4 m plus 30. If fewer than 20 letters are correctly identified, testing of the first 6 lines will be performed at 1 meter, and the final score is the sum of correctly identified letters obtained at 4 m and 1 m.

From enrollment to the end of study at 12 months
Change-from-baseline in National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) total score
時間枠:From enrollment to the end of study at 12 months

NEI-VFQ-25 questionnaire will be used to assess trial participants. Uniformly trained investigators will administer each item following standardized instructions. Participants will respond based on their actual visual function and daily life experience, and investigators will record responses truthfully. Domain scores and the composite score will be calculated according to the NEI-VFQ-25 scoring rules. All scores are transformed to a scale ranging from 0 to 100, with higher scores indicating better visual function and visual-related quality of life.

From enrollment to the end of study at 12 months

その他の成果指標

結果測定
メジャーの説明
時間枠
Change-from-baseline in geographic atrophy lesion area measured by fundus autofluorescence (FAF) at 1 year post-treatment
時間枠:From enrollment to the end of study at 12 months

Geographic atrophy lesion area will be assessed using fundus autofluorescence (FAF) imaging. Lesion area is measured in square millimeters (mm²).

From enrollment to the end of study at 12 months
Change-from-baseline in macular and graft-site retinal structure assessed by optical coherence tomography (OCT) at 1 year post-treatment
時間枠:From enrollment to the end of study at 12 months

OCT examination will be performed on the study eye to measure the central macular retinal thickness. Cross-sectional images of the macular region and cell graft area will be acquired to evaluate the integrity of retinal layers, RPE and outer retinal structure, as well as abnormal findings such as intraretinal or subretinal fluid.

From enrollment to the end of study at 12 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Songtao Yuan, M.D.、The First Affiliated Hospital with Nanjing Medical University

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年10月14日

一次修了 (推定)

2028年12月31日

研究の完了 (推定)

2028年12月31日

試験登録日

最初に提出

2026年1月9日

QC基準を満たした最初の提出物

2026年2月11日

最初の投稿 (実際)

2026年2月18日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月13日

QC基準を満たした最後の更新が送信されました

2026年11月11日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • JSPH-iPSCs-RPE-001

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する